|
1
|
Ying L, Chen Q, Wang Y, Zhou Z, Huang Y
and Qiu F: Upregulated MALAT-1 contributes to bladder cancer cell
migration by inducing epithelial-to-mesenchymal transition. Mol
Biosyst. 8:2289–2294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu
D and Huang Y: microRNA-203 suppresses bladder cancer development
by repressing bcl-w expression. FEBS J. 278:786–792. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Egerod FL, Bartels A, Fristrup N, Borre M,
Ørntoft TF, Oleksiewicz MB, Brünner N and Dyrskjøt L: High
frequency of tumor cells with nuclear Egr-1 protein expression in
human bladder cancer is associated with disease progression. BMC
Cancer. 9:3852009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Said N, Sanchez-Carbayo M, Smith SC and
Theodorescu D: RhoGDI2 suppresses lung metastasis in mice by
reducing tumor versican expression and macrophage infiltration. J
Clin Invest. 122:1503–1518. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Djuranovic S, Nahvi A and Green R: A
parsimonious model for gene regulation by miRNAs. Science.
331:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Leva G and Croce CM: The role of
microRNAs in the tumorigenesis of ovarian cancer. Front Oncol.
3:1532013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanke M, Hoefig K, Merz H, Feller AC,
Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin T, Dong W, Huang J, Pan Q, Fan X,
Zhang C and Huang L: MicroRNA-143 as a tumor suppressor for bladder
cancer. J Urol. 181:1372–1380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noguchi S, Yasui Y, Iwasaki J, Kumazaki M,
Yamada N, Naito S and Akao Y: Replacement treatment with
microRNA-143 and −145 induces synergistic inhibition of the growth
of human bladder cancer cells by regulating PI3K/Akt and MAPK
signaling pathways. Cancer Lett. 328:353–361. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Majid S, Dar AA, Saini S, Deng G, Chang I,
Greene K, Tanaka Y, Dahiya R and Yamamura S: MicroRNA-23b functions
as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS
One. 8:e676862013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K,
Xu H and Jiang S: miR-24-3p and miR-27a-3p promote cell
proliferation in glioma cells via cooperative regulation of MXI1.
Int J Oncol. 42:757–766. 2013.PubMed/NCBI
|
|
18
|
Pan B, Chen Y, Song H, Xu Y, Wang R and
Chen L: Mir-24-3p downregulation contributes to VP16-DDP resistance
in small-cell lung cancer by targeting ATG4A. Oncotarget.
6:317–331. 2015.PubMed/NCBI
|
|
19
|
Meng F-L, Wang W and Jia W-D: Diagnostic
and prognostic significance of serum miR-24-3p in HBV-related
hepatocellular carcinoma. Med Oncol. 31:1772014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Y, Liu Y, Du L, Li J, Qu A, Zhang X,
Wang L and Wang C: Down-regulation of miR-24-3p in colorectal
cancer is associated with malignant behavior. Med Oncol.
32:3622015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu K, Wang J, Song Y, Zhao S, Liu H, Tang
D, Pan B, Zhao H and Zhang Q: miRNA-24-3p promotes cell
proliferation and inhibits apoptosis in human breast cancer by
targeting p27Kip1. Oncol Rep. 34:995–1002. 2015.PubMed/NCBI
|
|
22
|
Hua F, Xue J, Lü X and Hu Z: DEDD
decreases Smad3 activity, promotes tumor cell apoptosis and
inhibits proliferation. Yao Xue Xue Bao. 48:680–685. 2013.(In
Chinese). PubMed/NCBI
|
|
23
|
He L, Zhong G and Zhu B: microRNA-15b
expressed in lung cancer-infiltrated CD8-positive memory T cell
inhibit cell apoptosis by repressing DEDD. Eur J Cancer (Suppl).
S147. 2013.
|
|
24
|
Carstens JL, Lovisa S and Kalluri R:
Microenvironment-dependent cues trigger miRNA-regulated feedback
loop to facilitate the EMT/MET switch. J Clin Invest.
124:1458–1460. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv Q, Hua F and Hu Z-W: DEDD, a novel
tumor repressor, reverses epithelial-mesenchymal transition by
activating selective autophagy. Autophagy. 8:1675–1676. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv Q, Wang W, Xue J, Hua F, Mu R, Lin H,
Yan J, Lv X, Chen X and Hu ZW: DEDD interacts with PI3KC3 to
activate autophagy and attenuate epithelial-mesenchymal transition
in human breast cancer. Cancer Res. 72:3238–3250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang L, Lai YK, Zhang J, Wang H, Lin MC,
He ML and Kung HF: Targeting S100P inhibits colon cancer growth and
metastasis by Lentivirus-mediated RNA interference and proteomic
analysis. Mol Med. 17:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Paris PL, Chen J, Ngo V, Yao H,
Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next
generation sequencing of pancreatic cyst fluid microRNAs from low
grade-benign and high grade-invasive lesions. Cancer Lett.
356:404–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stahlhut C and Slack FJ: MicroRNAs and the
cancer phenotype: Profiling, signatures and clinical implications.
Genome Med. 5:1112013. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ichimi T, Enokida H, Okuno Y, Kunimoto R,
Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama
K, et al: Identification of novel microRNA targets based on
microRNA signatures in bladder cancer. Int J Cancer. 125:345–352.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo
Z, Dong W, Huang J and Lin T: MicroRNA-125b suppresses the
development of bladder cancer by targeting E2F3. Int J Cancer.
128:1758–1769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adam L, Zhong M, Choi W, Qi W, Nicoloso M,
Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al:
miR-200 expression regulates epithelial-to-mesenchymal transition
in bladder cancer cells and reverses resistance to epidermal growth
factor receptor therapy. Clin Cancer Res. 15:5060–5072. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xue J-F, Hua F, Lv Q, Lin H, Wang ZY, Yan
J, Liu JW, Lv XX, Yang HZ and Hu ZW: DEDD negatively regulates
transforming growth factor-β1 signaling by interacting with Smad3.
FEBS Lett. 584:3028–3034. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JC, Schickling O, Stegh AH, Oshima RG,
Dinsdale D, Cohen GM and Peter ME: DEDD regulates degradation of
intermediate filaments during apoptosis. J Cell Biol.
158:1051–1066. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schutte B, Henfling M and Ramaekers FC:
DEDD association with cytokeratin filaments correlates with
sensitivity to apoptosis. Apoptosis. 11:1561–1572. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Klionsky DJ: Autophagy: From phenomenology
to molecular understanding in less than a decade. Nat Rev Mol Cell
Biol. 8:931–937. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huett A, Goel G and Xavier RJ: A systems
biology viewpoint on autophagy in health and disease. Curr Opin
Gastroenterol. 26:302–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li ZY, Yang Y, Ming M and Liu B:
Mitochondrial ROS generation for regulation of autophagic pathways
in cancer. Biochem Biophys Res Commun. 414:5–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu JJ, Lin M, Yu JY, Liu B and Bao JK:
Targeting apoptotic and autophagic pathways for cancer
therapeutics. Cancer Lett. 300:105–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kuma A, Matsui M and Mizushima N: LC3, an
autophagosome marker, can be incorporated into protein aggregates
independent of autophagy: Caution in the interpretation of LC3
localization. Autophagy. 3:323–328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pankiv S, Clausen TH, Lamark T, Brech A,
Bruun JA, Outzen H, Øvervatn A, Bjørkøy G and Johansen T:
p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of
ubiquitinated protein aggregates by autophagy. J Biol Chem.
282:24131–24145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ichimura Y, Kumanomidou T, Sou YS,
Mizushima T, Ezaki J, Ueno T, Kominami E, Yamane T, Tanaka K and
Komatsu M: Structural basis for sorting mechanism of p62 in
selective autophagy. J Biol Chem. 283:22847–22857. 2008. View Article : Google Scholar : PubMed/NCBI
|
